From STAT: Proove Biosciences, which sold dubious DNA tests to predict opioid addiction risk, has been placed into court-ordered receivership for restructuring and asset sale. Experts and former employees have expressed doubts about the validity of Proove’s genetic tests as well as the company’s questionable business practices, such as coercing patients to take unnecessary DNA tests.
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.